Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

INTRODUCTION: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). METHODS: Patients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks fo...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Alzheimers Dement (Amst)
Egile Nagusiak: Carlson, Christopher, Siemers, Eric, Hake, Ann, Case, Michael, Hayduk, Roza, Suhy, Joyce, Oh, Joonmi, Barakos, Jerome
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2016
Gaiak:
Neuroimaging
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879647/
https://ncbi.nlm.nih.gov/pubmed/27239538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dadm.2016.02.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak